10-Q: Bioxytran Reports Q1 2024 Results, Cites Ongoing Efforts to Secure Funding

Bioxytran, Inc. announces its financial results for the quarter ended March 31, 2024, highlighting ongoing efforts to develop therapeutic molecules and address financial challenges.

Summary

• Bioxytran, Inc. reported its financial results for the first quarter of 2024.
• The company is focused on developing therapeutic drugs for hypoxia and viral diseases.
• Bioxytran's subsidiary, Pharmalectin, is developing a glyco-virology platform technology called ProLectin.
• The company's IND for ProLectin-M was approved by the FDA, with trials expected to start in Q1 2024, pending funding.
• Bioxytran's Acelluar Oxygen Carrier (AOC) BXT-25 has been successfully tested in animals.
• The company had cash of $10,024 as of March 31, 2024, and a negative working capital of $1,105,877.
• The company has incurred cumulative net losses of $16,297,931.
• Management plans to seek additional capital through private placements and public offerings.
• The company generated a net loss in the three months ended March 31, 2024 of $800,329.
• The company's management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive developments in drug development, the company's financial situation is precarious, raising concerns about its ability to continue operations without additional funding.

Positives

• FDA approval of IND for ProLectin-M indicates regulatory progress.
• Successful animal testing of BXT-25 suggests potential for the Acelluar Oxygen Carrier.
• Conversion of loans and accounts payable to equity improved the company's liabilities position.
• Management team reducing compensation to conserve cash.

Negatives

• The company has a limited cash position of $10,024 as of March 31, 2024.
• The company has a negative working capital of $1,105,877.
• The company has incurred cumulative net losses of $16,297,931.
• The company generated a net loss in the three months ended March 31, 2024 of $800,329.
• The company's auditors have identified material weaknesses in internal controls.
• The company's management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• Failure to raise sufficient capital could force the company to curtail or cease operations.
• The company faces potential dilution to shareholders from convertible notes and warrant exercises.
• Material weaknesses in internal control over financial reporting could lead to misstatements in financial statements.
• The company's management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.

Future Outlook

The company intends to raise additional capital through private placements and public offerings to fund operations and continue product development. The company is planning a Private Placement Offering under Regulation D in the order of three (3) million dollars in first half of 2024.

Management Comments

• The management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.

Industry Context

Bioxytran operates in the competitive pharmaceutical industry, focusing on niche areas like hypoxia and viral diseases. The development of ProLectin and BXT-25 aligns with the growing demand for innovative therapies in these areas.

Comparison to Industry Standards

• It is difficult to compare Bioxytran's results directly to industry standards due to its early stage and specific focus areas.
• Larger pharmaceutical companies like Pfizer or Moderna have significantly more resources for research and development.
• Smaller biotech companies with similar focuses may be more relevant comparators, but specific financial data is needed for a detailed analysis.
• The success of ProLectin and BXT-25 will depend on clinical trial outcomes and regulatory approvals, which are key milestones in the pharmaceutical industry.

Management Changes

Legal Proceedings

• The Company may become involved in certain legal proceedings and claims which arise in the normal course of business.

Related Party Transactions

• During the three months ended March 31, 2024, there was $ 10,000 in transactions with affiliates.
• The Company had at March 31, 2024 loan agreements calling for an 8% interest with two of its affiliates, one loan is for $ 35,070 with an accrued interest of $ 1,064 , while the other is for $ 38,037 with an accrued interest of $ 33 .

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and convertible note conversions.
• Employees may be affected by cost-cutting measures if the company fails to secure additional funding.
• The success of clinical trials and regulatory approvals will impact patients who could benefit from the company's therapies.
• Creditors face increased risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company intends to raise additional capital through private placements and public offerings.
• The company plans to continue the development of ProLectin and BXT-25.
• The company expects the ProLectin-M trial to start in Q1 2024, pending funding.
• The company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats as funding permits.

Key Dates

Keywords

Bioxytran, Pharmalectin, BXT-25, ProLectin, clinical stage pharmaceutical, hypoxia, viral diseases, financial results, funding, IND, FDA, convertible notes, stock plan, warrants